Justin Meng Ko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Justin Meng Ko has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Brett King
Yale School of Medicine New Haven Connecticut USA
5 shared publications - Natasha Atanaskova Mesinkovska
Department of Dermatology, University of California, Irvine, Irvine, California
5 shared publications - Roxana Daneshjou
Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA
5 shared publications - Alexis Amano
Division of Primary Care and Population Health Department of Medicine Stanford University School of Medicine Palo Alto, CA United States
4 shared publications - Ana Calugar
Department of Quality, Stanford Health Care, Stanford, CA, United States
4 shared publications - Bernice Y. Kwong
Department of Dermatology, Stanford University, Stanford, California
4 shared publications
Latest Publications
- 14 November 2026
- Published by Springer Nature in Health and Technology
- p. 1-14
A multimodal deep learning system for automated dermoscopic classification and evidence-grounded clinical reporting
- 14 November 2026
- Published by Springer Nature in Health and Technology
- p. 1-14
A multimodal deep learning system for automated dermoscopic classification and evidence-grounded clinical reporting
- Open Access
- 3 November 2026
- Published by Elsevier in JID Innovations
What people with psoriasis talk about online: Insights from a digital ethnography of lived experience
- 3 November 2026
- Published by Elsevier in JID Innovations
Open AccessWhat people with psoriasis talk about online: Insights from a digital ethnography of lived experience
- Open Access
- 23 September 2025
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e84676
Patient satisfaction, side effects, and other reactions reported by adult men prescribed compounded, topical finasteride via a national telehealth platform: A retrospective analysis of real world data (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Topical minoxidil and oral finasteride are approved by the FDA for the treatment of male androgenetic alopecia (AGA). Concerns about adverse events related to the use of oral finasteride have led to some apprehension about the treatment. Topical finasteride, though not FDA-approved, has demonstrated efficacy and safety in a limited number of clinical trials and may be a promising alternative, such that compounding pharmacies and telehealth companies in the United States now offer access to topical finasteride for patients with AGA. Objective: The current real world, retrospective study is to our knowledge the largest to date on patient satisfaction and tolerability associated with novel combinations of topical finasteride and topical minoxidil for the treatment of male AGA. Methods: We conducted a retrospective analysis of patient data collected during routine clinical follow-up via the platform between April 1, 2021 and April 30, 2025 to assess the frequency of side effects and other possible medication reactions associated with the use of compounded, topical finasteride and minoxidil available via the Hims & Hers platform. Data were gathered from two sources: 1) a follow-up check-in sent to patients approximately 130 days following the initiation of treatment; 2) unprompted communications sent via in-app or web-based messaging from patients to their care team. Patient satisfaction with treatment, frequency of any side effect, frequency of specific side effects, need for a higher level of care, and treatment discontinuation due to a side effect were extracted from the data sources. Results: 638,629 male patients with AGA received a prescription for a compounded, topical finasteride and minoxidil product between April 1, 2021 and April 30, 2025. Of 151,352 (23.7%) who completed a follow-up check-in, 121,615 (80.4%) reported being satisfied with treatment and 4,034 (2.7%) reported experiencing a side effect. Of all 638,629 patients, 230 (0.04%) sent their care team a message (outside of check-ins) indicating a side effect or other possible medication reaction. No patients reported seeking a higher level of care or discontinuing treatment due to such an occurrence. Conclusions: Patients prescribed novel formulations of compounded, topical finasteride and minoxidil for the treatment of AGA via a national telehealth platform reported satisfaction with treatment and tolerated it well. Future research should include RCTs to assess the efficacy, safety, and tolerability of topical finasteride.
- 23 September 2025
- Published by JMIR Publications Inc. in JMIR Dermatology
- Vol. 9, e84676
Open AccessPatient satisfaction, side effects, and other reactions reported by adult men prescribed compounded, topical finasteride via a national telehealth platform: A retrospective analysis of real world data (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Topical minoxidil and oral finasteride are approved by the FDA for the treatment of male androgenetic alopecia (AGA). Concerns about adverse events related to the use of oral finasteride have led to some apprehension about the treatment. Topical finasteride, though not FDA-approved, has demonstrated efficacy and safety in a limited number of clinical trials and may be a promising alternative, such that compounding pharmacies and telehealth companies in the United States now offer access to topical finasteride for patients with AGA. Objective: The current real world, retrospective study is to our knowledge the largest to date on patient satisfaction and tolerability associated with novel combinations of topical finasteride and topical minoxidil for the treatment of male AGA. Methods: We conducted a retrospective analysis of patient data collected during routine clinical follow-up via the platform between April 1, 2021 and April 30, 2025 to assess the frequency of side effects and other possible medication reactions associated with the use of compounded, topical finasteride and minoxidil available via the Hims & Hers platform. Data were gathered from two sources: 1) a follow-up check-in sent to patients approximately 130 days following the initiation of treatment; 2) unprompted communications sent via in-app or web-based messaging from patients to their care team. Patient satisfaction with treatment, frequency of any side effect, frequency of specific side effects, need for a higher level of care, and treatment discontinuation due to a side effect were extracted from the data sources. Results: 638,629 male patients with AGA received a prescription for a compounded, topical finasteride and minoxidil product between April 1, 2021 and April 30, 2025. Of 151,352 (23.7%) who completed a follow-up check-in, 121,615 (80.4%) reported being satisfied with treatment and 4,034 (2.7%) reported experiencing a side effect. Of all 638,629 patients, 230 (0.04%) sent their care team a message (outside of check-ins) indicating a side effect or other possible medication reaction. No patients reported seeking a higher level of care or discontinuing treatment due to such an occurrence. Conclusions: Patients prescribed novel formulations of compounded, topical finasteride and minoxidil for the treatment of AGA via a national telehealth platform reported satisfaction with treatment and tolerated it well. Future research should include RCTs to assess the efficacy, safety, and tolerability of topical finasteride.
- 22 July 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 43 (4) , 541-552
Artificial Intelligence and Deep Learning for Skin Image Analysis
- 22 July 2025
- Published by Elsevier in Dermatologic Clinics
- Vol. 43 (4) , 541-552
Artificial Intelligence and Deep Learning for Skin Image Analysis
- 22 May 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (6)
Multimodal Image Dataset for AI-Based Skin Cancer (MIDAS) Benchmarking
- 22 May 2025
- Published by Massachusetts Medical Society in NEJM AI
- Vol. 2 (6)
Multimodal Image Dataset for AI-Based Skin Cancer (MIDAS) Benchmarking
- 29 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Trends in level of service provided by advanced practice clinicians and dermatologists in outpatient setting, 2012–2020
- 29 April 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-3
Trends in level of service provided by advanced practice clinicians and dermatologists in outpatient setting, 2012–2020
- 30 October 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (5) , 1205-1208.e4
DDI-2: A Diverse Skin Condition Image Dataset Representing Self-Identified Asian Patients
- 30 October 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (5) , 1205-1208.e4
DDI-2: A Diverse Skin Condition Image Dataset Representing Self-Identified Asian Patients
- Open Access
- 26 April 2024
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 10, e51279
Telehealth Utilization and Associations in the United States During the Third Year of the COVID-19 Pandemic: Population-Based Survey Study in 2022
Background: The COVID-19 pandemic rapidly changed the landscape of clinical practice in the United States; telehealth became an essential mode of health care delivery, yet many components of telehealth use remain unknown years after the disease’s emergence. Objective: We aim to comprehensively assess telehealth use and its associated factors in the United States. Methods: This cross-sectional study used a nationally representative survey (Health Information National Trends Survey) administered to US adults (≥18 years) from March 2022 through November 2022. To assess telehealth adoption, perceptions of telehealth, satisfaction with telehealth, and the telehealth care purpose, we conducted weighted descriptive analyses. To identify the subpopulations with low adoption of telehealth, we developed a weighted multivariable logistic regression model. Results: Among a total of 6252 survey participants, 39.3% (2517/6252) reported telehealth use in the past 12 months (video: 1110/6252, 17.8%; audio: 876/6252, 11.6%). The most prominent reason for not using telehealth was due to telehealth providers failing to offer this option (2200/3529, 63%). The most common reason for respondents not using offered telehealth services was a preference for in-person care (527/578, 84.4%). Primary motivations to use telehealth were providers’ recommendations (1716/2517, 72.7%) and convenience (1516/2517, 65.6%), mainly for acute minor illness (600/2397, 29.7%) and chronic condition management (583/2397, 21.4%), yet care purposes differed by age, race/ethnicity, and income. The satisfaction rate was predominately high, with no technical problems (1829/2517, 80.5%), comparable care quality to that of in-person care (1779/2517, 75%), and no privacy concerns (1958/2517, 83.7%). Younger individuals (odd ratios [ORs] 1.48-2.23; 18-64 years vs ≥75 years), women (OR 1.33, 95% CI 1.09-1.61), Hispanic individuals (OR 1.37, 95% CI 1.05-1.80; vs non-Hispanic White), those with more education (OR 1.72, 95% CI 1.03-2.87; at least a college graduate vs less than high school), unemployed individuals (OR 1.25, 95% CI 1.02-1.54), insured individuals (OR 1.83, 95% CI 1.25-2.69), or those with poor general health status (OR 1.66, 95% CI 1.30-2.13) had higher odds of using telehealth. Conclusions: To our best knowledge, this is among the first studies to examine patient factors around telehealth use, including motivations to use, perceptions of, satisfaction with, and care purpose of telehealth, as well as sociodemographic factors associated with telehealth adoption using a nationally representative survey. The wide array of descriptive findings and identified associations will help providers and health systems understand the factors that drive patients toward or away from telehealth visits as the technology becomes more routinely available across the United States, providing future directions for telehealth use and telehealth research.
- 26 April 2024
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 10, e51279
Open AccessTelehealth Utilization and Associations in the United States During the Third Year of the COVID-19 Pandemic: Population-Based Survey Study in 2022
Background: The COVID-19 pandemic rapidly changed the landscape of clinical practice in the United States; telehealth became an essential mode of health care delivery, yet many components of telehealth use remain unknown years after the disease’s emergence. Objective: We aim to comprehensively assess telehealth use and its associated factors in the United States. Methods: This cross-sectional study used a nationally representative survey (Health Information National Trends Survey) administered to US adults (≥18 years) from March 2022 through November 2022. To assess telehealth adoption, perceptions of telehealth, satisfaction with telehealth, and the telehealth care purpose, we conducted weighted descriptive analyses. To identify the subpopulations with low adoption of telehealth, we developed a weighted multivariable logistic regression model. Results: Among a total of 6252 survey participants, 39.3% (2517/6252) reported telehealth use in the past 12 months (video: 1110/6252, 17.8%; audio: 876/6252, 11.6%). The most prominent reason for not using telehealth was due to telehealth providers failing to offer this option (2200/3529, 63%). The most common reason for respondents not using offered telehealth services was a preference for in-person care (527/578, 84.4%). Primary motivations to use telehealth were providers’ recommendations (1716/2517, 72.7%) and convenience (1516/2517, 65.6%), mainly for acute minor illness (600/2397, 29.7%) and chronic condition management (583/2397, 21.4%), yet care purposes differed by age, race/ethnicity, and income. The satisfaction rate was predominately high, with no technical problems (1829/2517, 80.5%), comparable care quality to that of in-person care (1779/2517, 75%), and no privacy concerns (1958/2517, 83.7%). Younger individuals (odd ratios [ORs] 1.48-2.23; 18-64 years vs ≥75 years), women (OR 1.33, 95% CI 1.09-1.61), Hispanic individuals (OR 1.37, 95% CI 1.05-1.80; vs non-Hispanic White), those with more education (OR 1.72, 95% CI 1.03-2.87; at least a college graduate vs less than high school), unemployed individuals (OR 1.25, 95% CI 1.02-1.54), insured individuals (OR 1.83, 95% CI 1.25-2.69), or those with poor general health status (OR 1.66, 95% CI 1.30-2.13) had higher odds of using telehealth. Conclusions: To our best knowledge, this is among the first studies to examine patient factors around telehealth use, including motivations to use, perceptions of, satisfaction with, and care purpose of telehealth, as well as sociodemographic factors associated with telehealth adoption using a nationally representative survey. The wide array of descriptive findings and identified associations will help providers and health systems understand the factors that drive patients toward or away from telehealth visits as the technology becomes more routinely available across the United States, providing future directions for telehealth use and telehealth research.
- 4 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (10) , 2298-2301
Dermatologists’ Perspectives and Usage of Large Language Models in Practice: An Exploratory Survey
- 4 April 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (10) , 2298-2301
Dermatologists’ Perspectives and Usage of Large Language Models in Practice: An Exploratory Survey
- Open Access
Crowdsourcing Dermatology Images with Google Search Ads: Creating a Real-World Skin Condition Dataset
Background: Health datasets from clinical sources do not reflect the breadth and diversity of disease in the real world, impacting research, medical education, and artificial intelligence (AI) tool development. Dermatology is a suitable area to develop and test a new and scalable method to create representative health datasets. Methods: We used Google Search advertisements to invite contributions to an open access dataset of images of dermatology conditions, demographic and symptom information. With informed contributor consent, we describe and release this dataset containing 10,408 images from 5,033 contributions from internet users in the United States over 8 months starting March 2023. The dataset includes dermatologist condition labels as well as estimated Fitzpatrick Skin Type (eFST) and Monk Skin Tone (eMST) labels for the images. Results: We received a median of 22 submissions/day (IQR 14-30). Female (66.72%) and younger (52% < age 40) contributors had a higher representation in the dataset compared to the US population, and 32.6% of contributors reported a non-White racial or ethnic identity. Over 97.5% of contributions were genuine images of skin conditions. Dermatologist confidence in assigning a differential diagnosis increased with the number of available variables, and showed a weaker correlation with image sharpness (Spearman's P values <0.001 and 0.01 respectively). Most contributions were short-duration (54% with onset < 7 days ago ) and 89% were allergic, infectious, or inflammatory conditions. eFST and eMST distributions reflected the geographical origin of the dataset. The dataset is available at github.com/google-research-datasets/scin . Conclusion: Search ads are effective at crowdsourcing images of health conditions. The SCIN dataset bridges important gaps in the availability of representative images of common skin conditions.
Open AccessCrowdsourcing Dermatology Images with Google Search Ads: Creating a Real-World Skin Condition Dataset
Background: Health datasets from clinical sources do not reflect the breadth and diversity of disease in the real world, impacting research, medical education, and artificial intelligence (AI) tool development. Dermatology is a suitable area to develop and test a new and scalable method to create representative health datasets. Methods: We used Google Search advertisements to invite contributions to an open access dataset of images of dermatology conditions, demographic and symptom information. With informed contributor consent, we describe and release this dataset containing 10,408 images from 5,033 contributions from internet users in the United States over 8 months starting March 2023. The dataset includes dermatologist condition labels as well as estimated Fitzpatrick Skin Type (eFST) and Monk Skin Tone (eMST) labels for the images. Results: We received a median of 22 submissions/day (IQR 14-30). Female (66.72%) and younger (52% < age 40) contributors had a higher representation in the dataset compared to the US population, and 32.6% of contributors reported a non-White racial or ethnic identity. Over 97.5% of contributions were genuine images of skin conditions. Dermatologist confidence in assigning a differential diagnosis increased with the number of available variables, and showed a weaker correlation with image sharpness (Spearman's P values <0.001 and 0.01 respectively). Most contributions were short-duration (54% with onset < 7 days ago ) and 89% were allergic, infectious, or inflammatory conditions. eFST and eMST distributions reflected the geographical origin of the dataset. The dataset is available at github.com/google-research-datasets/scin . Conclusion: Search ads are effective at crowdsourcing images of health conditions. The SCIN dataset bridges important gaps in the availability of representative images of common skin conditions.